{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:27:15Z","timestamp":1787063235853,"version":"build-2736575974"},"reference-count":126,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5\u2009years. As the S-enantiomer of ketamine, esketamine\u2019s dosing guidelines and strict medical supervision stem from prior research on ketamine\u2019s use in depression and history as a recreational drug. Despite initial concerns, long-term clinical studies have not documented instances of abuse, misuse, addiction or withdrawal, and the same was found in case reports or subsamples of high-risk populations with comorbidities such as substance use disorder or alcohol use disorder. Esketamine has proven to be safe and well tolerated without fostering new-onset substance use in vulnerable groups. Real-world studies reinforced these observations, reporting no adverse events (AEs) related to pharmacological interactions of esketamine with any other substance, and no new-onset drug or alcohol misuse, craving, misuse or diversion of use. Reports of esketamine craving remain rare, with only one case report documented in 2022. Most drug-related AEs reported in pharmacovigilance databases are those identified in the product\u2019s technical data sheet and with known reported frequency. More importantly, no register of illicit acquisition of esketamine or its tampering for obtaining ketamine or other altered products was found in our search. Overall, our review confirms esketamine\u2019s safety across diverse patient populations, reassuring its responsible use and the scarcity of reports of abuse or misuse since its introduction to the market.<\/jats:p>","DOI":"10.1177\/20420986241310685","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T14:07:40Z","timestamp":1738159660000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Is there a risk of esketamine misuse in clinical practice?"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1421-7385","authenticated-orcid":false,"given":"Carlos","family":"Roncero","sequence":"first","affiliation":[{"name":"Health Science Faculty, European University Miguel de Cervantes (UEMC), C\/Padre Julio Chevalier, 2, 47012, Valladolid, Spain"},{"name":"Psychiatry Unit, School of Medicine, University of Salamanca, Salamanca, Spain"},{"name":"Network of Research in Primary Care of Addictions (RIAPAD) Instituto Carlos III, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3926-8472","authenticated-orcid":false,"given":"Milton","family":"Merizalde-Torres","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Salamanca, Spain"},{"name":"Psychiatry Service, University Healthcare Complex of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9821-7958","authenticated-orcid":false,"given":"N\u00e9stor","family":"Szerman","sequence":"additional","affiliation":[{"name":"World Association on Dual Disorders. World Psychiatric Association, Section on Dual Disorders, Madrid, Spain"},{"name":"Institute of Psychiatry and Mental Health, University Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6222-4761","authenticated-orcid":false,"given":"Marta","family":"Torrens","sequence":"additional","affiliation":[{"name":"Network of Research in Primary care of Addictions (RIAPAD)"},{"name":"School of Medicine, Universitat de Vic-Central de Catalunya, Vic, Spain"},{"name":"Medicine and Life Sciences Department, Universitat Pompeu Fabra, Barcelona, Spain"},{"name":"Addiction Research Group (GRAd), Neuroscience Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-8602","authenticated-orcid":false,"given":"Pablo","family":"Vega","sequence":"additional","affiliation":[{"name":"Institute for Addictions, Madrid Salud, Madrid City Council, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0904-788X","authenticated-orcid":false,"given":"Pilar","family":"Andres-Olivera","sequence":"additional","affiliation":[{"name":"Psychiatry Unit, School of Medicine, University of Salamanca, Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), Salamanca, Spain"},{"name":"Psychiatry Service, University Healthcare Complex of Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7566-5678","authenticated-orcid":false,"given":"Francisco","family":"Javier \u00c1lvarez","sequence":"additional","affiliation":[{"name":"Pharmacology Department, School of Medicine, University of Valladolid, Valladolid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"bibr1-20420986241310685","unstructured":"GHDx. Global health data exchange, http:\/\/ghdx.healthdata.org\/gbd-results-tool (2024, accessed January 2024)."},{"key":"bibr2-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.08.036"},{"key":"bibr3-20420986241310685","first-page":"21","volume":"420","author":"Alonso J","year":"2004","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"bibr4-20420986241310685","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4088\/JCP.0207e03","volume":"68","author":"Alonso J","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"bibr5-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2021.04.022"},{"key":"bibr6-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2237-x"},{"key":"bibr7-20420986241310685","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S198774"},{"key":"bibr8-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"bibr9-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1007\/s12264-016-0081-2"},{"key":"bibr10-20420986241310685","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2015.17.2\/dionescu"},{"key":"bibr11-20420986241310685","author":"European Medicines Agency","year":"2023","journal-title":"EMA\/CHMP\/185423\/2010 Rev 3"},{"key":"bibr12-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12959"},{"key":"bibr13-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905"},{"key":"bibr14-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13035"},{"key":"bibr15-20420986241310685","unstructured":"Fundaci\u00f3n Espa\u00f1ola de Psiquiatr\u00eda y Salud Mental. La depresi\u00f3n, un reto para la salud p\u00fablica en Europa, https:\/\/fepsm.org\/noticias\/detalles\/91\/la-depresion-un-reto-para-la-salud-publica-en-europa (2017, accessed January 2024)."},{"key":"bibr16-20420986241310685","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10061307"},{"key":"bibr17-20420986241310685","doi-asserted-by":"crossref","first-page":"66","DOI":"10.20882\/adicciones.868","volume":"30","author":"Tirado Mu\u00f1oz J","year":"2018","journal-title":"Adicciones"},{"key":"bibr18-20420986241310685","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11071846"},{"key":"bibr19-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.06.022"},{"key":"bibr20-20420986241310685","unstructured":"European Medicines Agency. Spravato, INN-esketamine \u2013 Summary of product characteristics, www.ema.europa.eu\/en\/documents\/product-information\/spravato-epar-product-information_en.pdf (2019, accessed January 2024)."},{"key":"bibr21-20420986241310685","unstructured":"US Food Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic, http:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified (2019, accessed January 2024)."},{"key":"bibr22-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189"},{"key":"bibr23-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039"},{"key":"bibr24-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.10.008"},{"key":"bibr25-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172"},{"key":"bibr26-20420986241310685","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891"},{"key":"bibr27-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(92)90248-3"},{"key":"bibr28-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1007\/BF03011442"},{"key":"bibr29-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-196601000-00007"},{"key":"bibr30-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1002\/cpt196563279"},{"key":"bibr31-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/57.2.197"},{"key":"bibr32-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.7b00074"},{"key":"bibr33-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.9b02575"},{"key":"bibr34-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1965.tb00219.x"},{"key":"bibr35-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1021\/jo01020a019"},{"key":"bibr36-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199702000-00014"},{"key":"bibr37-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2008.00965.x"},{"key":"bibr38-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01193"},{"key":"bibr39-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7321-7_1"},{"key":"bibr40-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-1166(199901)14:1<3::AID-GPS897>3.0.CO;2-7"},{"key":"bibr41-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(93)90355-J"},{"key":"bibr42-20420986241310685","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.22.1034"},{"key":"bibr43-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0173(97)00061-1"},{"key":"bibr44-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(00)89070-7"},{"key":"bibr45-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1007\/s001090000077"},{"key":"bibr46-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpsc.2017.04.006"},{"key":"bibr47-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001016"},{"key":"bibr48-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2013.03.030"},{"key":"bibr49-20420986241310685","volume":"2013","author":"Atigari OV","year":"2013","journal-title":"BMJ Case Rep"},{"key":"bibr50-20420986241310685","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09049"},{"key":"bibr51-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"bibr52-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13030392"},{"key":"bibr53-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.05.003"},{"key":"bibr54-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.08.038"},{"key":"bibr55-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.04.029"},{"key":"bibr56-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1949454"},{"key":"bibr57-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.2000.tb01076.x"},{"key":"bibr58-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2016.07.008"},{"key":"bibr59-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02394.x"},{"key":"bibr60-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1903305"},{"key":"bibr61-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1186\/s12910-016-0087-3"},{"key":"bibr62-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620937899"},{"key":"bibr63-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01116-3"},{"key":"bibr64-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.11.023"},{"key":"bibr65-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(96)00042-9"},{"key":"bibr66-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01093-2"},{"key":"bibr67-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012414"},{"key":"bibr68-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19040423"},{"key":"bibr69-20420986241310685","first-page":"176","volume-title":"CADTH issues in emerging health technologies","author":"Tibensky BN"},{"key":"bibr70-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.psiq.2020.01.002"},{"key":"bibr71-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyab084"},{"key":"bibr72-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-024-01770-7"},{"key":"bibr73-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2012.11028.x"},{"key":"bibr74-20420986241310685","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S391096"},{"key":"bibr75-20420986241310685","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m13191"},{"key":"bibr76-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa068"},{"key":"bibr77-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304145"},{"key":"bibr78-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.09.043"},{"key":"bibr79-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2020.89"},{"key":"bibr80-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30394-3"},{"key":"bibr81-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.06.003"},{"key":"bibr82-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32832a8eb2"},{"key":"bibr83-20420986241310685","unstructured":"European Medicines Agency. Spravato \u2013 Medicine overview. European public assessment report (EPAR). EMA\/614876\/2019. Committee for Medicinal Products for Human Use (CHMP). Assessment report. Procedure No. EMEA\/H\/C\/004535\/0000, https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/spravato-epar-public-assessment-report_en.pdf (2019, accessed January 2024)."},{"key":"bibr84-20420986241310685","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14318"},{"key":"bibr85-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.12.038"},{"key":"bibr86-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2023.08.498"},{"key":"bibr87-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2023.02.010"},{"key":"bibr88-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01381-x"},{"key":"bibr89-20420986241310685","volume-title":"NICE guidelines. Depression in adults: treatment and management","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"bibr90-20420986241310685","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S388392"},{"key":"bibr91-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2023.04.011"},{"key":"bibr92-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20081251"},{"key":"bibr93-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.13375"},{"key":"bibr94-20420986241310685","first-page":"8992697","volume":"2022","author":"Faruqui Z","year":"2022","journal-title":"Case Rep Psychiatry"},{"key":"bibr95-20420986241310685","doi-asserted-by":"publisher","DOI":"10.3390\/biom13091411"},{"key":"bibr96-20420986241310685","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.775670"},{"key":"bibr97-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043535"},{"key":"bibr98-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2013.08.009"},{"key":"bibr99-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2016.39"},{"key":"bibr100-20420986241310685","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci11070856"},{"key":"bibr101-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02761.x"},{"key":"bibr102-20420986241310685","first-page":"18","volume-title":"Ketamine revisited","author":"Patrycja K","year":"2021"},{"key":"bibr103-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2017.1371364"},{"key":"bibr104-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1159\/000510703"},{"key":"bibr105-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1159\/000506868"},{"key":"bibr106-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00928-1"},{"key":"bibr107-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b15-00243"},{"key":"bibr108-20420986241310685","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.849758"},{"key":"bibr109-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.01.002"},{"key":"bibr110-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12745"},{"key":"bibr111-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15467"},{"key":"bibr112-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2021.11.036"},{"key":"bibr113-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-023-01732-5"},{"key":"bibr114-20420986241310685","unstructured":"Janssen Scientific Affairs. SPRAVATO \u2013 Potential for abuse and diversion. Janssen Scientific Affairs, LLC, https:\/\/www.janssenscience.com\/products\/spravato\/medical-content\/spravato-potential-for-abuse-and-diversion (2023, accessed February 2024)."},{"key":"bibr115-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2071422"},{"key":"bibr116-20420986241310685","unstructured":"Janssen Research and Development. Crossover study to evaluate the abuse potential of intranasal esketamine compared to racemic intravenous ketamine in nondependent, recreational drug users [ClinicalTrials.gov Identifier: NCT02682225]. US National Institutes of Health, https:\/\/clinicaltrials.gov\/study\/NCT02682225 (2017, accessed February 2024)."},{"key":"bibr117-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1177\/0706743720970860"},{"key":"bibr118-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1080\/15622975.2020.1836399"},{"key":"bibr119-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00897-2"},{"key":"bibr120-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21111086"},{"key":"bibr121-20420986241310685","unstructured":"Schifano F. High-level discussion of polysubstance abuse; focus on prescription and OTC drug misuse. In: RADARS annual meeting, https:\/\/www.radars.org\/system\/events\/RADARS%28R%29%20System%202021%20Annual%20Scientific%20Meeting%20Program%20v3_1.pdf (2021, accessed February 2024)."},{"key":"bibr122-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2023.108075"},{"key":"bibr123-20420986241310685","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.657397"},{"key":"bibr124-20420986241310685","doi-asserted-by":"publisher","DOI":"10.2174\/1381612828666220510115209"},{"key":"bibr125-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2022.09.003"},{"key":"bibr126-20420986241310685","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-023-01577-5"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986241310685","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420986241310685","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986241310685","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:40:43Z","timestamp":1777592443000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420986241310685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":126,"alternative-id":["10.1177\/20420986241310685"],"URL":"https:\/\/doi.org\/10.1177\/20420986241310685","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"20420986241310685"}}